[go: up one dir, main page]

MX2016004575A - Metodos de modificacion de celulas huespedes. - Google Patents

Metodos de modificacion de celulas huespedes.

Info

Publication number
MX2016004575A
MX2016004575A MX2016004575A MX2016004575A MX2016004575A MX 2016004575 A MX2016004575 A MX 2016004575A MX 2016004575 A MX2016004575 A MX 2016004575A MX 2016004575 A MX2016004575 A MX 2016004575A MX 2016004575 A MX2016004575 A MX 2016004575A
Authority
MX
Mexico
Prior art keywords
methods
host cell
cell modification
host cells
nucleic acid
Prior art date
Application number
MX2016004575A
Other languages
English (en)
Other versions
MX371513B (es
Inventor
Michael Wacker
Michael Kowarik
Fabiana Fernandez
Original Assignee
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycovaxyn Ag filed Critical Glycovaxyn Ag
Publication of MX2016004575A publication Critical patent/MX2016004575A/es
Publication of MX371513B publication Critical patent/MX371513B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se describen métodos para insertar secuencias de ácidos nucleicos en las células huéspedes. También se describen en la presente células huéspedes genéticamente estables que comprenden secuencias de ácidos nucleicos insertadas y los métodos para utilizar estas células huéspedes en la generación de las proteínas.
MX2016004575A 2013-10-11 2014-10-13 Metodos de modificacion de celulas huespedes. MX371513B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361889672P 2013-10-11 2013-10-11
PCT/EP2014/071889 WO2015052344A1 (en) 2013-10-11 2014-10-13 Methods of host cell modification

Publications (2)

Publication Number Publication Date
MX2016004575A true MX2016004575A (es) 2016-07-12
MX371513B MX371513B (es) 2020-01-31

Family

ID=51726490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004575A MX371513B (es) 2013-10-11 2014-10-13 Metodos de modificacion de celulas huespedes.

Country Status (13)

Country Link
US (2) US11220676B2 (es)
EP (1) EP3055416B1 (es)
JP (1) JP2016533719A (es)
KR (1) KR20160062169A (es)
CN (1) CN106062203B (es)
BR (1) BR112016007727A8 (es)
CA (1) CA2926523C (es)
EA (1) EA201690529A1 (es)
ES (1) ES2778074T3 (es)
IL (1) IL244791A0 (es)
MX (1) MX371513B (es)
SG (1) SG11201602546RA (es)
WO (1) WO2015052344A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2945651T3 (pl) 2013-01-17 2018-08-31 Arsanis Biosciences Gmbh Przeciwciało swoiste wobec E.coli MDR
ES2778074T3 (es) 2013-10-11 2020-08-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
LT3110441T (lt) 2014-02-24 2024-04-25 Glaxosmithkline Biologicals S.A. Naujas polisacharidas ir jo panaudojimas
DK3131577T3 (da) * 2014-04-17 2020-07-13 Glaxosmithkline Biologicals Sa Modificerede værtsceller og anvendelser deraf
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201712678D0 (en) * 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
EP3492482A1 (en) 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae
CN108611306B (zh) * 2018-04-03 2021-05-25 华南农业大学 一种研究慢生根瘤菌的基因功能的方法
CN108531439B (zh) * 2018-04-16 2020-04-07 南京工业大学 一种大肠杆菌基因工程菌及其构建方法与应用
CN108774628B (zh) * 2018-07-02 2022-03-25 南开大学 合成致新生儿脑膜炎大肠杆菌糖蛋白结合疫苗的大肠杆菌工程菌及用途
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
PL3942028T3 (pl) 2019-03-18 2023-10-23 Janssen Pharmaceuticals, Inc. Sposób wytwarzania biokoniugatów polisacharydów antygenu O E. coli, zawierające je kompozycje oraz sposoby ich zastosowania
SG11202110301TA (en) 2019-03-18 2021-10-28 Janssen Pharmaceuticals Inc Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
JP7690257B2 (ja) * 2019-06-24 2025-06-10 トヨタ自動車株式会社 形質転換補助用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
WO2021165928A2 (en) * 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
KR102160203B1 (ko) * 2020-06-15 2020-09-25 서울시립대학교 산학협력단 데이노잔틴 고생산능을 갖는 변이 균주의 제조방법 및 온도제어를 이용한 데이노잔틴 대량생산 방법
WO2021259742A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
JP7517002B2 (ja) * 2020-09-10 2024-07-17 トヨタ自動車株式会社 形質転換体の製造方法及び形質転換方法
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
EP4237428A2 (en) * 2020-10-27 2023-09-06 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022087881A (ja) * 2020-12-02 2022-06-14 トヨタ自動車株式会社 形質転換用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
JP2022099419A (ja) * 2020-12-23 2022-07-05 トヨタ自動車株式会社 形質転換用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
JP7694022B2 (ja) * 2020-12-23 2025-06-18 トヨタ自動車株式会社 形質転換補助用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
CN113388596B (zh) * 2021-08-16 2021-12-07 翌圣生物科技(上海)股份有限公司 高保真Pfu DNA聚合酶突变体、其编码DNA及其在NGS中的应用
JP2024139548A (ja) * 2023-03-27 2024-10-09 株式会社豊田中央研究所 遺伝子発現方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311972B1 (en) 2005-05-11 2015-01-21 ETH Zurich Recombinant N-glycosylated proteins from procaryotic cells
CA2716187C (en) * 2008-02-20 2020-01-07 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
PL2501406T3 (pl) * 2009-11-19 2018-05-30 Glaxosmithkline Biologicals S.A. Biosyntetyczny układ wytwarzający immunogenne polisacharydy w komórkach prokariotycznych
NO2566507T3 (es) * 2010-05-06 2018-04-21
JP2014526449A (ja) 2011-09-06 2014-10-06 グリコヴァキシン アーゲー 原核細胞において製造されるバイオコンジュゲートワクチン
EP2771479B1 (en) * 2011-10-28 2020-01-08 Merck Sharp & Dohme Corp. Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
SG11201501391YA (en) * 2012-09-10 2015-03-30 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
ES2720040T3 (es) * 2012-10-12 2019-07-17 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
CN105008539B (zh) * 2012-11-07 2020-04-17 葛兰素史密丝克莱恩生物有限公司 通过酶缀合在大肠杆菌中生产重组疫苗
ES2778074T3 (es) 2013-10-11 2020-08-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras

Also Published As

Publication number Publication date
CN106062203B (zh) 2020-08-07
CA2926523C (en) 2023-09-26
BR112016007727A8 (pt) 2018-01-30
MX371513B (es) 2020-01-31
KR20160062169A (ko) 2016-06-01
SG11201602546RA (en) 2016-04-28
IL244791A0 (en) 2016-04-21
CN106062203A (zh) 2016-10-26
EP3055416A1 (en) 2016-08-17
US20220186196A1 (en) 2022-06-16
WO2015052344A1 (en) 2015-04-16
US20170121691A1 (en) 2017-05-04
BR112016007727A2 (pt) 2017-09-12
EA201690529A1 (ru) 2016-11-30
ES2778074T3 (es) 2020-08-07
JP2016533719A (ja) 2016-11-04
CA2926523A1 (en) 2015-04-16
US11220676B2 (en) 2022-01-11
EP3055416B1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
MX2016004575A (es) Metodos de modificacion de celulas huespedes.
MX2015004649A (es) Metodos de modificacion de celulas huesped.
MX2019005158A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
EP4303232A3 (en) Chimeric antigen receptor and methods of use thereof
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
MX2022002624A (es) Edicion del genoma sin nucleasas.
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
IN2014DN05963A (es)
GB2561496A (en) Devices and methods for simulating a function of a liver tissue
MX2016007797A (es) Metodos para integracion genomica.
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
IL241294A0 (en) Genetic expression of response in dendritic cells, preparations and methods of use
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
GB2562396A (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
MX351043B (es) Metodos para modificacion genomica.
NZ701099A (en) Ketol-acid reductoisomerase enzymes and methods of use
MY173953A (en) Recombinant host cells for the production of malonate
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2014089268A3 (en) Lgr5+ somatic stem cells
MX2021013104A (es) Variantes de lipasa y polinucleotidos que las codifican.
EP3321360A3 (en) Alpha-amylase variants and polynucleotides encoding same
MX356162B (es) Sistema de expresion y secrecion.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

FG Grant or registration